<DOC>
	<DOCNO>NCT02617849</DOCNO>
	<brief_summary>This multi-center , open-label , Phase II clinical trial evaluate pembrolizumab combination carboplatin/paclitaxel treatment unresectable locally advanced metastatic melanoma .</brief_summary>
	<brief_title>Pembrolizumab With Carboplatin/Paclitaxel Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>The subject must : 1 . Be willing able provide write informed consent trial . 2 . Be ≥ 18 year age day sign informed consent . 3 . Have histologically confirm diagnosis unresectable Stage III metastatic melanoma . Patients may diagnosis uveal melanoma . 4 . Have measurable disease base RECIST 1.1 . 5 . Have tumor sample ( FFPE archival newly obtain biopsy ) metastatic site available biomarker analysis . 6 . Have ECOG 0 1 . 7 . Demonstrate adequate organ function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥90 g/L ( may transfuse ) Serum creatinine OR CrCl ≤ 1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR ≤ 5 X ULN subject liver metastasis Albumin &gt; 2.5 mg/dL International Normalized Ratio ( INR ) Prothrombin Time ( PT ) Activated Partial Thromboplastin Time ( aPTT ) ≤ 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 8 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 9 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 10 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 11 . No known active chronic infection HIV , Hepatitis B , Hepatitis C. The subject must exclude participate trial subject : 1 . Has prior treatment advance unresectable metastatic melanoma . Prior treatment BRAF MEK inhibitor permit set . A washout least 5halflives ( median terminal halflife ) prior first dose trial treatment must elapse . 2 . Has receive prior therapy antiCTLA4 , antiPD1 , antiPDL1 , antiPDL2 agent . 3 . Has evidence symptomatic CNS lesion determine investigator . Patients asymptomatic lesion previously irradiate surgically resect eligible . 4 . Has know additional malignancy progress require active treatment . 5 . Has diagnosis immunodeficiency receive systemic steroid therapy ( &gt; 10 mg daily prednisone equivalent ) form immunosuppressive therapy within 7 day prior first dose trial treatment . Inhaled topical steroid , adrenal replacement dos ≤ 10 mg prednisone equivalent permit . 6 . Has ≥ Grade 2 peripheral neuropathy . 7 . Patients active autoimmune disease document history autoimmune disease syndrome require systemic steroid immunosuppressive agent . Patients vitiligo resolve childhood asthma/atopy exception rule . Patients require intermittent use bronchodilator local steroid injection would exclude study . Patients hypothyroidism stable hormone replacement exclude study . 8 . Has active infection require systemic therapy . 9 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 10 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 11 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 12 . Has know history active TB ( Bacillus Tuberculosis ) 13 . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>